exenatide and sitagliptin + exenatide and placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Mar 1, 2009 โ Apr 1, 2010
NCT ID
NCT00870194About exenatide and sitagliptin + exenatide and placebo
exenatide and sitagliptin + exenatide and placebo is a approved stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00870194. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00870194 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus